(Total Views: 495)
Posted On: 04/19/2020 1:19:55 PM
Post# of 153822
I like the logic of that opinion. Trust that I will be one of the individuals following his lead.
I have listened to NP say CYDY is a triple digit stock and I can tell from his tone that he is fully-committed to that valuation. I have informally estimated the peak sales numbers on just a percentage of the larger proposed indications, and post-approval, I tend to agree. But that thesis has not yet been validated with clinicals.
If enough mega blockbuster indications prove efficacious and win FDA approval (we're talking years here), then CYDY is on its way to becoming a very substantial company, and possibly even a BP. However, that's not going to happen with the company's current configuration, and I'm not sure the company is capable of successfully growing organically.
At certain point, if we're not too expensive, we might have to weigh cost/benefit of accepting an offer that discounts indications that have not yet received FDA approval, and that might experience competitive pressures even if they do.
I have listened to NP say CYDY is a triple digit stock and I can tell from his tone that he is fully-committed to that valuation. I have informally estimated the peak sales numbers on just a percentage of the larger proposed indications, and post-approval, I tend to agree. But that thesis has not yet been validated with clinicals.
If enough mega blockbuster indications prove efficacious and win FDA approval (we're talking years here), then CYDY is on its way to becoming a very substantial company, and possibly even a BP. However, that's not going to happen with the company's current configuration, and I'm not sure the company is capable of successfully growing organically.
At certain point, if we're not too expensive, we might have to weigh cost/benefit of accepting an offer that discounts indications that have not yet received FDA approval, and that might experience competitive pressures even if they do.
(1)
(0)
